实时磁共振成像引导下对流增强递送脂质体伊立替康治疗复发性高级别胶质瘤的Ⅰ期研究
这项Ⅰ期试验评估实时MRI引导下对流增强递送(CED)脂质体伊立替康和钆剂治疗复发性高级别胶质瘤的安全性和耐受性。18例WHO 3或4级复发性胶质瘤患者接受治疗,脂质体伊立替康总剂量20-680 mg、总体积2-17 ml,唯一剂量限制性毒性为3级卒中。作者认为该方案可行,实时MRI引导改善了导管放置和肿瘤覆盖,结果需进一步研究重复CED给药。
要点
- 18例复发性WHO 3或4级胶质瘤患者接受实时MRI引导CED脂质体伊立替康治疗。
- 脂质体伊立替康总剂量20-680 mg,总体积2-17 ml,浓度从20 mg/mL递增至40 mg/mL。
- 唯一剂量限制性毒性为3级卒中,作者认为该方案可行并需进一步研究重复给药。
核心结论
- 实时MRI引导下CED递送脂质体伊立替康治疗复发性高级别胶质瘤是可行的。
- 影像引导改善了CED导管放置和最佳肿瘤覆盖。
- 作者认为结果需进一步研究重复CED给药。
研究设计与样本
- 最初计划为3+3剂量递增、单次给药试验,基于固定药物剂量和体积设4个队列。
- 9例患者后方案修订,允许根据肿瘤大小调整研究药物的体积和剂量。
- 修订后设计为「个性化」药物体积,第一队列脂质体伊立替康浓度固定为20 mg/mL,第二队列递增至40 mg/mL。
- 共治疗18例复发性WHO 3或4级胶质瘤患者,肿瘤直径1-4 cm。
主要发现
- 基于肿瘤体积,脂质体伊立替康总剂量为20-680 mg,总体积为2-17 ml。
- 通过实时MRI引导和方案修订克服了技术挑战。
- 唯一剂量限制性毒性(DLT)为3级卒中。
- 文中报告了安全性和生存信息。
局限性
- 作者结论指出结果需进一步研究重复CED给药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Irinotecan demonstrates anti-tumor efficacy in preclinical glioma models but clinical results are modest due to drug delivery limitations. Convection enhanced delivery (CED) improves drug delivery by increasing intratumoral drug concentration. Real-time magnetic resonance imaging of infusate delivery during CED may optimize tumor coverage. This phase 1 trial examines the safety and tolerability of liposomal irinotecan and gadolinium delivered via CED using real-time MRI guidance in recurrent high-grade glioma patients. METHODS: Initially, a 3 + 3 dose-escalating, single dose trial was planned with 4 cohorts based on a fixed drug dose and volume. After 9 patients, a protocol amendment allowed for variable volume and dose of the study agent based on tumor size. The amended design specified 'personalized' drug volume but fixed concentration of 20 mg/mL of liposomal irinotecan in the first cohort escalating to 40 mg/mL in the second cohort. RESULTS: Eighteen patients with recurrent WHO grade 3 or 4 gliomas (diameter 1-4 cm) were treated. Based on the tumor volume, the total dose of liposomal irinotecan was 20-680 mg in a total volume of 2-17 ml. Technical challenges were overcome by real-time MRI guidance and protocol amendment. The only dose-limiting toxicity (DLT) was a grade 3 stroke. Safety and survival information is presented. CONCLUSIONS: CED of liposomal irinotecan using real-time MRI in patients with recurrent high-grade glioma is feasible. Image-guidance allowed for improved placement of CED cannulas and optimal tumor coverage. Our results warrant further study with repeat CED dosing.
引用
- Narsinh KH, Kumar K, Bankiewicz K, et al. A phase I study of convection-enhanced delivery (CED) of liposomal-irinotecan using real-time magnetic resonance imaging in patients with recurrent high-grade glioma. J Neurooncol. 2025. PMID: 39760796. doi:10.1007/s11060-024-04904-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。